VCYT - Veracyte, Inc.
22.33 -0.59 (-2.57%)
After hours: 4:34PM EDT
| Previous Close | 23.36 |
| Open | 23.36 |
| Bid | 22.90 x 1400 |
| Ask | 22.93 x 800 |
| Day's Range | 22.66 - 23.69 |
| 52 Week Range | 5.56 - 26.75 |
| Volume | 262,169 |
| Avg. Volume | 616,150 |
| Market Cap | 942.211M |
| Beta (3Y Monthly) | -0.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.62 |
| Earnings Date | Apr 30, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.33 |
- Zacks•2 days ago
Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Benzinga•2 days ago
The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) Moleculin Biotech Inc (NASDAQ: MBRX ) (announcement ...
- Business Wire•3 days ago
Veracyte Receives Regulatory Authorization to Offer Envisia Genomic Classifier for Patients in New York State
Novel Genomic Test Helps Improve Diagnosis of Idiopathic Pulmonary Fibrosis
- Business Wire•3 days ago
Veracyte Names Alfred Bowie, Jr., Ph.D. as Vice President, Corporate and Business Development
Veracyte, Inc. , a leading genomic diagnostics company, today announced that it has named Alfred “Freddie” Bowie, Jr., Ph.D., as vice president, corporate and business development.
- Simply Wall St.•6 days ago
Can You Imagine How Chuffed Veracyte's (NASDAQ:VCYT) Shareholders Feel About Its 297% Share Price Gain?
The Veracyte, Inc. (NASDAQ:VCYT) share price has had a bad week, falling 10%. But that doesn't undermine the rather lovely longer-term return, if you measure over the last three years. In fact, the share price is up a...
- Investopedia•16 days ago
These Cannabis and China ETFs are Leading the 2019 Rally
Stock investors seeking even bigger returns than the 2019 bull rally might look at five ETFs that have already gained at least 40% year-to-date, approaching triple the 15% pace of the S&P 500. The winners ...
- Business Wire•17 days ago
Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype
The Afirma GSC was developed using Veracyte’s novel RNA whole-transcriptome sequencing and machine learning platform. Most Hürthle cell cases yield inconclusive cytopathology results and, prior to Veracyte’s next-generation genomic test, most of these patients typically required surgery to rule out thyroid cancer.
- Business Wire•22 days ago
Veracyte to Release First Quarter 2019 Financial Results on April 30, 2019
Veracyte, Inc. today announced that it will release its financial results for the first quarter 2019 after the close of market on Tuesday, April 30, 2019. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 5:00 p.m.
- Business Wire•24 days ago
Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF
The Envisia classifier is the first commercially available test that may help distinguish IPF from other ILDs, without the need for risky surgery. The Envisia classifier recently received Medicare coverage, making it the first test of its kind for improving IPF diagnosis to be covered for the nation’s 55 million Medicare patients.
- Business Wire•28 days ago
Veracyte Announces Participation in the 18th Annual Needham Healthcare Conference
Veracyte, Inc. , a leading genomic diagnostics company, today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 18th Annual Needham Healthcare Conference in New York City on Wednesday, April 10, 2019 at 8:00 a.m.
- Investopedia•28 days ago
3 Small Biotech Stocks Hitting New Highs
Biotech funds have stalled at key retracement levels after strong first quarter bounces and could sell off in the coming weeks, but small biotech stocks are still glued to the top of market performance lists, hitting new highs while posting outsized returns. It's wise to keep one eye on the research calendar when trading small biotech stocks with compounds in the pipeline, hitting the sidelines ahead of key dates because these issues can drop 50% or more overnight after adverse results. New York-based Axsome Therapeutics, Inc. (AXSM) researches and develops compounds and therapies for Alzheimer's disease and other central nervous system disorders.
- GlobeNewswire•29 days ago
Research Report Identifies Alamos Gold, Thermo Fisher Scientific, Veracyte, Air Lease, Carlisle Companies, and Medidata Solutions with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•last month
Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer
The findings shed new light on the genomic underpinning of this rare, but aggressive, form of thyroid cancer and were presented today at ENDO 2019, the Endocrine Society's annual meeting, which is being held March 23-26 in New Orleans. “Our findings are important because they help us better understand the genomic drivers of medullary thyroid cancer,” said Steven G. Waguespack, M.D., professor of internal medicine and pediatrics at University of Texas MD Anderson Cancer Center in Houston, who presented the new data in a guided poster session.
- Zacks•last month
Will Veracyte Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Veracyte.
- Business Wire•last month
Veracyte Announces Sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro Expedition
Veracyte, Inc. (VCYT), a leading genomics diagnostics company, today announced its “Summit” level sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro expedition as part of the company’s expanded efforts to combat this disease. Through its sponsorship, the company is supporting “Team Kilimanjaro,” a group of biotechnology executives and investors that will climb Africa’s highest peak in late July 2019 to raise money for Fred Hutchinson Cancer Research Center. The Climb to Fight Cancer’s Team Kilimanjaro expedition is organized and led by Luke Timmerman, founder and editor of the Timmerman Report, a leading biotechnology newsletter.
- Business Wire•last month
Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019
Veracyte, Inc. announced today that new data derived from the Afirma® Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer , will be presented at ENDO 2019, the Endocrine Society’s annual meeting.
- Simply Wall St.•last month
Veracyte, Inc.’s (NASDAQ:VCYT) Shift From Loss To Profit
Veracyte, Inc.'s (NASDAQ:VCYT): Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The US$851m market-cap company announced a latest loss of -US$23.0m on 31 DecemberRead More...
- Zacks•last month
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
Veracyte (VCYT) delivered earnings and revenue surprises of 38.46% and 5.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks•2 months ago
Zacks.com featured highlights include: Radiant, Great Lakes, Clarus, Veracyte and First BanCorp
Zacks.com featured highlights include: Radiant, Great Lakes, Clarus, Veracyte and First BanCorp
- Business Wire•2 months ago
Veracyte Receives Final Medicare Coverage Policy for Envisia Genomic Classifier
Veracyte, Inc. (VCYT) announced today that it has received a final Medicare local coverage determination (LCD) for the Envisia™ Genomic Classifier. The policy was issued through the Palmetto GBA MolDx program and will become effective April 1, 2019, making the Envisia classifier covered for the nation’s 55 million Medicare patients. The Envisia classifier is the first commercially available test of its kind to improve diagnosis of idiopathic pulmonary fibrosis (IPF) and is Veracyte’s third genomic test to receive a Medicare-covered designation since the company’s founding in 2008.
- Zacks•2 months ago
5 Stocks With Recent Price Strength to Maximize Your Gains
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of VCYT earnings conference call or presentation 25-Feb-19 10:00pm GMT
Q4 2018 Veracyte Inc Earnings Call
Motley Fool•2 months agoVeracyte Inc (VCYT) Q4 2018 Earnings Conference Call Transcript
VCYT earnings call for the period ending December 31, 2018.
- Business Wire•2 months ago
Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook
2018 Revenue Grew 28% to $92 million
- ACCESSWIRE•2 months ago
Veracyte Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Veracyte Inc (NASDAQ: VCYT ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, 2019 at 5:00 PM Eastern ...
